By Greg Avery
Denver Business Journal
AstraZeneca ramps up as biotech bounces back in Colorado
By Greg Avery
CBSA Forum Attracted Industry, Political Leaders Focused on Life Science Innovation
Inaugural Colorado Life Science Innovation Forum included spotlight on entrepreneurial companies with SiVEC Biotechnologies named as winner of venture capital showcase
Bio2 Medical wins FDA clearance for embolism-snaring Angel catheter
VetDC Achieves Key Regulatory Milestone, Nears FDA Approval of TANOVEA for Canine Lymphoma
FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today
announced that the Company has received three major technical section complete letters for TanoveaTM (rabacfosadine) from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM). Upon approval, Tanovea will be the first on-label therapeutic
option for use in dogs with lymphoma, one of the most common cancers afflicting companion animals today.
Ovarian Cancer Drug from Clovis gets FDA Priority Review
The FDA scheduled a decision to be made on the drug by Feb. 23, 2017, the Boulder, Colorado-based company said Tuesday in a statement. Rucaparib was designated a breakthrough therapy by the FDA in April 2015. The FDA gives that designation to drugs that may bring substantial improvement over available treatments and is intended to speed up the process of development and review.
ARCA Biopharma Announces 100th Patient Randomized Into the Genetic-AF Phase 2B/3 Clinical Trial
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for
cardiovascular diseases, today announced that the 100th patient has been randomized into GENETIC-AF, a seamless design Phase 2B/3 clinical trial evaluating
Gencaro (bucindolol hydrochloride) as potentially the first genetically-targeted treatment for atrial fibrillation. This represents two-thirds of the
minimum number of patients needed for a pre-specified Phase 2B interim efficacy analysis.
VisuGen Global LLC Wins National Science Foundation (NSF) SBIR Phase I Award
Aurora, CO: VisuGen Global LLC has been awarded $222,236 to support the development of an “Environmental water on site microbial contaminant sensor.” The
purpose of the proposal is to advance the development of VisuGen Global’s proprietary molecular approach for a rapid on-site test that will monitor
E. coli from 100 milliliters of water in less than an hour.
CBSA Forum Highlights Impact of Life Science on Colorado’s Innovation Economy
Inaugural Colorado Life Science Innovation Forum showcases the state’s pioneering spirit, entrepreneurial courage and patient-first focus, offering robust discussions and networking opportunities Continue Reading
ArcherDX NGS assays receive conditional approval by New York State
ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today that two Archer® FusionPlex® NGS assays
have received conditional approval from the New York State Department of Health for clinical use by Memorial Sloan Kettering Cancer Center (MSK). The
assays, which are powered by ArcherDX’s proprietary Anchored Multiplex PCR (AMP™) targeted enrichment chemistry, were designed for MSK to identify
known and novel gene fusions in blood cancers, sarcomas and solid tumors.
Peak Serum, Inc., Supplier of Fetal Bovine Serum for CGMP, Clinical Trial Research and Diagnostics Applications, Launches New eCommerce Website
COLORADO - August 5, 2016 - Peak Serum, Inc., a privately owned and independent supplier of life science laboratory products, announced today the launch
of its new website. The new website introduces the ability to purchase the company’s four core products online: US Origin Fetal Bovine Serum (FBS),
USDA Origin FBS, Pure Premium FBS and Newborn Calf Serum.
- CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado
- New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life
- Flagship Bioscience: Is PD-L1 Harmonization on the Horizon?
- InDevR Launches Next-Generation Software for the Cypher One™ System
- ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update